Navigation Links
New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
Date:1/19/2011

CAMBRIDGE, Mass., Jan. 19, 2011 /PRNewswire/ -- Health Alert Communications, www.healthalert.net, announces the publication of its groundbreaking report, HIV/AIDS: The Jennings Report – Redefining the Size, Scope, and Scale of the AIDS Epidemic by Forensic Review of the Medical Literature, available from MarketResearch.com and ResearchAndMarkets.com, the world's leading distributors of market intelligence.

The report synthesizes the scientific and medical literature to conceptually redefine the size of the AIDS epidemic and related markets:  a potentially invaluable, alternative perspective for decision-makers responsible for funding endeavors related to HIV-related products and/or interventions.

HIV/AIDS: The Jennings Report distills the knowledge garnered from a forensic review of the medical literature – over 3,000 scientific and medical articles – the collaborative efforts of thousands of scientists spanning 30 years. This document reports on all the relevant disciplines relating to HIV/AIDS, presenting information previously overlooked, and reconfiguring the medical and scientific data into a new conceptual constellation.  The precision of this qualitative information sloughs away many long-lived misconceptions, and confutes the theorems upon which the quantitative statistical models are based.

"A series of interlocking fallacies have distorted scientific and public perceptions of HIV and the AIDS epidemic, such that scientific and medical data are viewed through a warped lens," says Chris Jennings, Author and Proprietor of Health Alert Communications.  "The scientific literature is clear:  (1) New York City is the epicenter of the AIDS epidemic; (2) the theory that HIV came from monkeys is a fallacy (the theory that AIDS originated in African monkeys arose from an incident of laboratory contamination); and (3) the African AIDS epidemic-as-holocaust never manifested."

The information presented by HIV/AIDS: The Jennings Report has powerful implications that could affect funding and research prerogatives, potentially enabling more practical allocation of resources.

HIV/AIDS: The Jennings Report is available at:  http://www.marketresearch.com/product/display.asp?xs=r&productid=2879615 and http://www.researchandmarkets.net/reportinfo.asp?r=1477240.  Both websites provide a Table of Contents.

About Health Alert Communications: (www.healthalert.net) published two AIDS books, one favorably reviewed by the New England Journal of Medicine, that sold over 165,000:  both adopted as reference texts by world-renowned hospitals; city, state, and federal health agencies; colleges, nursing schools, and public health schools; and medical bookstores.

About Chris Jennings:  www.healthalert.net/Chris_Jennings.html

About MarketResearch.com:  www.marketresearch.com/corporate/aboutus/default.asp?SID=57797214-499932699-515748933

About ResearchAndMarkets.com:  www.researchandmarkets.com/info/about.aspContacts:Jacki Katzman Health Alert Communications+ 1.781.223.1364pr@healthalert.net
'/>"/>

SOURCE Health Alert Communications
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
2. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
3. Long Term Care Pharmacy Alliance Concerned with Proposed CMS Rule; New Study Confirms LTCPA Position
4. St. Francis Hospital to be Part of Major Nationwide Study Using a Catheter-Based Aortic Valve Replacement
5. CVS Caremark Study Finds Patients with Complex Therapies Struggle to Stay Adherent to their Medications
6. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
7. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
8. CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending
9. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
10. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
11. Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... name the Creator responds to and which He does not. Yisrayl says with so ... one is the true name, but he says with a little Scripture, backed with a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. ... alliance with B. Braun Medical Inc. , a leader in infusion therapy and ... with as many as 90 percent of hospital patients receiving a peripheral IV catheter ...
Breaking Medicine News(10 mins):